Worth reading
30Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Conditional
How definitive the wording is.Agreements reached under this partnership
Business allianceDetails of the alliance
- 1
License agreement for the exclusive sale of Trilostane Tablets "Asuka" in Taiwan
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
About the partner
Business DescriptionA company operating an animal-health pharmaceutical business in Taiwan
LocationTaiwan
Contract Date2 October 2026Alliance start dateSales are scheduled to begin after regulatory approval is obtained
| Item | Details |
|---|---|
| Alliance partner's business activities | A company operating an animal-health pharmaceutical business in Taiwan |
| Alliance partner's location | Taiwan |
| Type of alliance | Business alliance |
| Details of the alliance | License agreement for the exclusive sale of Trilostane Tablets "Asuka" in Taiwan |
| Contract Date | 2 October 2026 |
| Alliance start date | Sales are scheduled to begin after regulatory approval is obtained |
Items this document does not state (17)
Name of alliance partnerAlliance partner's capitalAlliance partner's net salesAlliance partner's operating incomeNumber of shares acquiredAcquisition priceShareholding ratioOverview of the joint ventureOwnership ratioDispatch of directors and officersContract PeriodNumerical targets under the allianceShareholding PolicyDate of board resolutionShare Acquisition Date and Payment DateImpact on Business PerformanceChange in major shareholders
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The agreement is intended to contribute to the development of veterinary care in Taiwan and the health of companion animals through expansion into the Taiwanese market, while supporting the group's overseas business expansion, particularly in Asia, and creating new business opportunities and enhancing corporate value.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.